Pacific Biosciences of California Inc. [PACB] moved down -11.34: Why It’s Important

Related

Pacific Biosciences of California Inc. [NASDAQ: PACB] closed the trading session at $14.70 on 01/11/22. The day’s price range saw the stock hit a low of $13.85, while the highest price level was $14.93. The company report on January 11, 2022 that PacBio and Berry Genomics Announce Collaboration to Bring Long Read Desktop Sequencing Instrument to the Clinical Market in China.

New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Berry Genomics to purchase at least 50 instruments at product launch.

The stocks have a year to date performance of -28.15 percent and weekly performance of -22.55 percent. The stock has been moved at -46.66 percent over the last six months. The stock has performed -29.60 percent around the most recent 30 days and changed -39.51 percent over the most recent 3-months.

If compared to the average trading volume of 2.40M shares, PACB reached to a volume of 12099344 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Pacific Biosciences of California Inc. [PACB]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $40.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 06, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Market Perform. The new note on the price target was released on October 15, 2021, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $45, while Canaccord Genuity analysts kept a Buy rating on PACB stock. On February 11, 2021, analysts increased their price target for PACB shares from 20 to 52.

The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 1.79, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 27.32. The Price to Book ratio for the last quarter was 3.53, with the Price to Cash per share for the same quarter was set at 4.78.

PACB stock trade performance evaluation

Pacific Biosciences of California Inc. [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.55. With this latest performance, PACB shares dropped by -29.60% in over the last four-week period, additionally sinking by -46.66% over the last 6 months – not to mention a drop of -55.77% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 27.71, with the RSI for the last a single of trading hit 21.64, and the three-weeks RSI is set at 31.59 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 22.79, while it was recorded at 16.44 for the last single week of trading, and 27.29 for the last 200 days.

Pacific Biosciences of California Inc. [PACB]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -132.31 and a Gross Margin at +41.28. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at +37.27.

Return on Total Capital for PACB is now -42.25, given the latest momentum, and Return on Invested Capital for the company is 12.51. Return on Equity for this stock inclined to 15.06, with Return on Assets sitting at 10.46. When it comes to the capital structure of this company, Pacific Biosciences of California Inc. [PACB] has a Total Debt to Total Equity ratio set at 12.52. Additionally, PACB Total Debt to Total Capital is recorded at 11.13, with Total Debt to Total Assets ending up at 10.15. Long-Term Debt to Equity for the company is recorded at 11.23, with the Long-Term Debt to Total Capital now at 9.98.

Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc. [PACB] managed to generate an average of $71,367 per employee. Receivables Turnover for the company is 4.91 with a Total Asset Turnover recorded at a value of 0.28.Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 20.00 and a Current Ratio set at 20.30.

Earnings per share (EPS) analysis for Pacific Biosciences of California Inc. [PACB] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Pacific Biosciences of California Inc. [PACB]: Insider Ownership positions

There are presently around $2,772 million, or 84.30% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 22,723,075, which is approximately 10.944% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 17,996,649 shares of the stock with an approximate value of $264.55 million in PACB stocks shares; and BLACKROCK INC., currently with $237.16 million in PACB stock with ownership of nearly -0.349% of the company’s market capitalization.

Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 123 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 26,010,828 shares. Additionally, 113 investors decreased positions by around 8,958,223 shares, while 43 investors held positions by with 153,633,087 shares. The mentioned changes placed institutional holdings at 188,602,138 shares, according to the latest SEC report filing. PACB stock had 26 new institutional investments in for a total of 6,282,382 shares, while 38 institutional investors sold positions of 2,962,577 shares during the same period.